IBL News

The research group led by Dr. Chihiro Akiba, Department of Neurosurgery, Juntendo University has reported in the following study that change of Amyloidβ1-42 (Aβ42) toxic conformer ratio in CSF with idiopathic Normal Pressure Hydrocephalus (iNPH)* patients predicts a long-term cognitive outcome.

Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus. Akiba C et al. J Alzheimers Dis. 2018;63(3):989-1002. PMID: 29710721

2 cohort results are reported in this research.

The first cohort consists of Alzheimer's disease patients (AD, N = 17), iNPH patients (iNPH, N = 17) and cognitively normal control (CN, N = 12).  Aβ42 toxic conformer ratio (Aβ42 toxic conformer/Aβ42×100) in the iNPH group was significantly higher than the CN group and significantly lower than the AD group.

The second cohort consists of 51 patients with iNPH and it was divided into low level pTau (Age-adjusted) and high level one. The high level group showed cognitive decline for 2 years while the low level one showed its improvement after 1 year after shunting. 

The low level pTau group was divided into the group decreased and increased of Aβ42 conformer ratio for 1 year after CSF shunting for further investigation. In the result, the decreased group showed high ratio of improvement of cognitive capability while the increased group was observed decline the capability after 2 years. 

From this outcome, it has been suggested that a long-term cognitive outcome can be predicted from the change of Aβ42 conformer ratio in CSF with iNPH.

*idiopathic Normal Pressure Hydrocephalus (iNPH) is a disease that squeezes brain and causes disability by abnormal CSF accumulation in brain. The symptoms are included gait disturbance, dementia, and urinary incontinence. The syndrome can be improved by CSF shunting.

#27709 Human Amyloid β Toxic Oligomer Assay Kit - IBL was used for measurement of Aβ42 toxic conformer in this study.

We have also a comprehensive product lineup in Alzheimer’s disease.

We hope that we can support your research.
Please feel free to contact us.

Sales Department
Diagnostic and Research Reagents Division
Immuno-Biological Laboratories Co., Ltd.
TEL: +81-274-50-8666
Email: do-ibl@ibl-japan.co.jp